Recent Updates
Recently added Catalysts

MGd

Phase 3

Metastatic Cancer | Small molecule | Oncology |AbbVie Inc.|Last Updated: Oct 31, 2013

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedCONTROLLED
Total Trials1
Total Enrollment430
FDA Designations
No designations recorded
Clinical trial landscape

MGd · 1 trial · 1 indication

Phase 3 1
NCT00003563Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Brain MetastasesMetastatic Cancer
COMPLETED430 Analytics
PHASE3COMPLETED
Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Brain Metastases
Metastatic Cancer
NCT00003563430
Unlock trial analytics
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelFACTORIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
WBRTEXPERIMENTAL3 Gy of WBRT daily for a total of 10 days
MGdEXPERIMENTALIV does of 5.0 mg/kg MGd plus WBRT
Interventions
NameTypeDescription
WBRTRADIATION3 GY of WBRT daily for a total of 10 days
MGdDRUG5.0 mg /kg MGd plus WBRT
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites35

DISEASE CHARACTERISTICS: Histologically proven solid tumor with parenchymal brain metastasis Solitary metastasis eligible only if refused surgery or surgical resection deemed inappropriate No leptomeningeal metastases or subarachnoid spread of tumor No small cell lung cancer, germ cell tumors, lymph...

Countries:United StatesCanada
Unlock Eligibility Criteria
Competitive Landscape -Cancer 5 trials (matched to "Metastatic Cancer")
CompanyTickerTrialsLead PhaseDrugs
GE Healthcare Technologies Inc.GEHC1PHASE1GEH200520 / GEH200521 - Part A
Zimmer Biomet Holdings, Inc.ZBH1 - Undisclosed
Ascentage Pharma Group International Unsponsored ADRAAPG1PHASE1Olverembatinib
Unlock Competitive Intelligence